SLC9A7

Across TCGA pan-cancer cohorts, SLC9A7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC9A7 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC9A7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC9A7 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where SLC9A7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.280	0.538	.004	20	view →
CCRCC	OS	Quartile	All	0.761	1.000	.003	14	view →
GBM	DFS	Median	All	0.846	0.650	.007	5	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	4	view →
LSCC	OS	Tertile	II,III,IV	0.562	0.851	.031	2	view →
UCEC	OS	Quartile	All	1.000	0.889	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC9A7–PDAC (DFS)

Open the PDAC breakdown →